Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
== Pests and diseases == Clematis species are susceptible to several pests and diseases. Clematis wilt, a stem rot caused by the fungus Phoma clematidina, causes dramatic wilting and death of whole branches, although many species are resistant to it. The species of this genus are also alternate hosts of Puccinia recondita f.sp. tritici. C. mandshurica specifically is known to provide inoculum transferrable to wheat in the former eastern Soviet territories, and several of this genus are hosts for several other P. recondita strains and other Puccinia. Other pests and diseases include powdery mildew, viruses, slugs and snails, scale insects, aphids, earwigs, and green flower disease, which is usually caused by infection with a phytoplasma, a type of bacterium.
Platelet basic protein (PBP) is a protein that in humans is encoded by the gene PPBP (previously CXCL7). PBP is a precursor protein that is cleaved into multiple distinct active proteins, notable Connective tissue-activating peptide III (CTAP-III), Beta-thromboglobulin (Beta-TG), Neutrophil-activating peptide 2 (NAP-2), TC-1, and TC-2. PPBP is first translated into the precursor molecule pro-platelet basic protein (PPBP), the first 34 amino acids of which correspond to the signal peptide, while the remaining amino acid residues at positions 35-128 compose PBP. PBP is a protein that is released in large amounts from platelets following their activation. It stimulates various processes including mitogenesis, synthesis of extracellular matrix, glucose metabolism and synthesis of plasminogen activator.
While the initial consolidation of Air Force laboratories reduced overhead and budgetary pressure, another push towards a unified laboratory structure came in the form of the National Defense Authorization Act for Fiscal Year 1996, Section 277. This section instructed the Department of Defense to produce a five-year plan for consolidation and restructuring of all defense laboratories. The currently existing laboratory structure was created in October 1997 through the consolidation of Phillips Laboratory headquartered in Albuquerque, New Mexico, Wright Laboratory in Dayton, Ohio, Rome Laboratory (formerly Rome Air Development Center) in Rome, New York, and Armstrong Laboratory in San Antonio, Texas and the Air Force Office of Scientific Research (AFOSR). The single laboratory concept was developed and championed by Maj Gen Richard Paul, who was Director of Science & Technology for AFMC and Gen Henry Viccellio Jr, and then became the first Commander of AFRL.
The discovery of the new elements and the new data on neutron capture were initially kept secret on the orders of the US military until 1955 due to Cold War tensions. Nevertheless, the Berkeley team were able to prepare einsteinium and fermium by civilian means, through the neutron bombardment of plutonium-239, and published this work in 1954 with the disclaimer that it was not the first studies that had been carried out on those elements. The "Ivy Mike" studies were declassified and published in 1955. The first significant (submicrogram) amounts of einsteinium were produced in 1961 by Cunningham and colleagues, but this has not been done for fermium yet. The first isotope of mendelevium, 256Md (half-life 87 min), was synthesized by Albert Ghiorso, Glenn T. Seaborg, Gregory Robert Choppin, Bernard G. Harvey and Stanley Gerald Thompson when they bombarded an 253Es target with alpha particles in the 60-inch cyclotron of Berkeley Radiation Laboratory; this was the first isotope of any element to be synthesized one atom at a time. There were several attempts to obtain isotopes of nobelium by Swedish (1957) and American (1958) groups, but the first reliable result was the synthesis of 256No by the Russian group of Georgy Flyorov in 1965, as acknowledged by the IUPAC in 1992. In their experiments, Flyorov et al. bombarded uranium-238 with neon-22. In 1961, Ghiorso et al. obtained the first isotope of lawrencium by irradiating californium (mostly californium-252) with boron-10 and boron-11 ions.
=== Antagonists === Non-selective Caffeine Theophylline CGS-15943 Selective 8-Cyclopentyl-1,3-dimethylxanthine (CPX / 8-cyclopentyltheophylline) 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) 8-Phenyl-1,3-dipropylxanthine Bamifylline BG-9719 Tonapofylline (BG-9928) FK-453 FK-838 Rolofylline (KW-3902) N-0861 ISAM-CV202
Sources: en.wikipedia.org
The KRRC Rhodesians were in the forefront of the Allied column pursuing the retreating Axis forces after El Alamein, advancing through Tobruk, Gazala and Benghazi before reaching El Agheila on 24 November 1942. They patrolled around the Axis right flank until being withdrawn to Timimi in December. Tripoli fell to the Eighth Army on 23 January 1943, and six days later Allied forces reached Tunisia's south-eastern frontier, where Italian and German forces manned the Mareth Line, a series of fortifications built by the French in the 1930s.
Pre-adipocytes are undifferentiated fibroblasts that can be stimulated to form adipocytes. Studies have shed light into potential molecular mechanisms in the fate determination of pre-adipocytes although the exact lineage of adipocyte is still unclear. The variation of body fat distribution resulting from normal growth is influenced by nutritional and hormonal status dependent on intrinsic differences in cells found in each adipose depot. Mesenchymal stem cells can differentiate into adipocytes, connective tissue, muscle or bone. The precursor of the adult cell is termed a lipoblast, and a tumor of this cell type is known as a lipoblastoma.
==== Conditions for higher transfer results ==== Nearly complete transfer in systems implementing countercurrent exchange, is only possible if the two flows are, in some sense, "equal". For a maximum transfer of substance concentration, an equal flowrate of solvents and solutions is required. For maximum heat transfer, the average specific heat capacity and the mass flow rate must be the same for each stream. If the two flows are not equal, for example if heat is being transferred from water to air or vice versa, then, similar to cocurrent exchange systems, a variation in the gradient is expected because of a buildup of the property not being transferred properly.
Javits (1952), former ambassador and permanent U.S. representative to the Conference on Disarmament in Geneva 2001–2003; U.S. permanent representative to the Organisation for the Prohibition of Chemical Weapons 2003–2009 James D. Theberge (1952), former U.S. ambassador to Chile and Nicaragua G. Norman Anderson (1954), former U.S. ambassador to Sudan David J. Bardin (1954), deputy administrator of the Federal Energy Administration; commissioner of the New Jersey Department of Environmental Protection William Haddad (1954), political operative, lobbyist, and journalist, Peace Corps founding official, aide to the Kennedy family, and grandson-in-law of Franklin D. Roosevelt Richard E. Benedick (1955), president emeritus of the National Council for Science and the Environment, ambassador, and chief U.S. negotiator to the Montreal Protocol John L. Hirsch (1957), U.S. ambassador to Sierra Leone 1995–1998 Morton Halperin (1958), deputy assistant secretary of defense, director of policy planning for the U.S. State Department, and member of Richard Nixon's Enemies List Shelby Brewer (1959), assistant secretary of energy for nuclear energy 1981–1984 Benjamin Huberman (1959), acting director of the Office of Science and Technology Policy; acting science advisor to the president in 1981 Pat Mullins (1959), chairman of the Republican Party of Virginia Constantine Menges (1960), national security aide to Ronald Reagan James E.
Sources: en.wikipedia.org
Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.
High pressure can be used to disable harmful microorganisms and spoilage enzymes while retaining the food's fresh appearance, flavor, texture and nutrients. By 2005, the process was being used for products ranging from orange juice to guacamole to deli meats and widely sold. Depending on temperature and pressure settings, HP processing can achieve either pasteurization-equivalent log reduction or go all the way to achieve sterilization of all microbes.
=== Market === The global instant coffee market was valued at US$34.16 Billion in 2026. In 2025, Asia-Pacific accounted for 39% of the instant coffee market, Europe 28%, North America 24% and Middle East and Africa 9%. A 2014 article said that as a percentage of coffee sold, instant coffee accounted for 1% of the market in Italy, 4% in France, 7% in the US, and 77% in the UK. The high proportion in the UK was attributed to coffee, a novelty to a tea-drinking nation, being introduced in the form of instant coffee by US troops in Britain during World War II.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.